Matter Bio Files First IND for Lm-LLO-TT, Advancing First-in-Human Phase 1/2a Study in Pancreatic Cancer

IND submission marks Matter Bio's transition toward clinical stage and advances its lead Listeria-based immunotherapy into one of oncology's highest-need indications SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- Matter Bio today announced the submission of its first Investigational New Drug...